# Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2).

> **NCT03370640** · PHASE1 · COMPLETED · sponsor: **Sumitomo Pharma Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** SEP-363856

## Key facts

- **NCT ID:** NCT03370640
- **Lead sponsor:** Sumitomo Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-29
- **Primary completion:** 2018-09-20
- **Final completion:** 2018-09-20
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03370640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03370640, "Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2).". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03370640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*